Herpes simplex virus type 1 vector (HSV-1 vector)

Herpes simplex virus type 1 vector is an engineered viral system derived from the neurotropic HSV-1, designed for the delivery of large genetic payloads to mammalian cells, with particular efficacy in neurons due to HSV's natural tendency to infect neural tissue[1][3][6]. These vectors can be replication-defective or attenuated to minimize host immune responses or toxicity, and are used for both gene therapy (including long-term neuronal gene expression) and oncolytic cancer therapies[2][4][6]. Key features include their broad host range, large DNA-carrying capacity, ability to deliver genes without permanent genome integration, and their use in research tracing neuronal circuits[2][1]. Safety concerns focus on immunogenicity, latent infection, potential recombination with wild virus, and delivery scope for clinical translation[1][4][6]. In summary: "Herpes simplex virus type 1 vector delivery system" is not a molecular target but a gene therapy tool; it should be properly categorized for structured knowledge as a vector system, not an endogenous protein or receptor.

Other names

Herpes simplex virus type 1 vectorHSV-1 vectorHSV-based vectorHerpes simplex virus vector

Gene delivery via viral entry, fusion, and nuclear transport of delivered DNA. Expression of therapeutic gene(s) in target cells. Oncolysis when engineered for anticancer therapy. Neuronal tracing through trans-synaptic movement.